ALKERMES PLC |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 24.05 USD | +0.80% |
|
-2.55% | -13.30% |
| May. 02 | UBS Adjusts Price Target on Alkermes to $21 From $23, Maintains Sell Rating | MT |
| May. 01 | Alkermes's Q1 Earnings, Revenue Grow But Miss Street View | MT |
Financials (USD)
| Sales 2024 * | 1.5B | Sales 2025 * | 1.51B | Capitalization | 4.07B |
|---|---|---|---|---|---|
| Net income 2024 * | 336M | Net income 2025 * | 350M | EV / Sales 2024 * | 2.21 x |
| Net cash position 2024 * | 748M | Net cash position 2025 * | 1.03B | EV / Sales 2025 * | 2.02 x |
| P/E ratio 2024 * |
12.4
x | P/E ratio 2025 * |
12.3
x | Employees | 2,100 |
| Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 95.07% |
More Fundamentals
* Assessed data
More news
Latest transcript on Alkermes plc
More recommendations
More press releases
| 1 day | +0.80% | ||
| 1 week | -2.55% | ||
| Current month | -2.00% | ||
| 1 month | -8.66% | ||
| 3 months | -10.06% | ||
| 6 months | -2.99% | ||
| Current year | -13.30% |
1 week
23.26
25.26
1 month
23.2627.56
Current year
23.2632.88
1 year
22.0133.71
3 years
21.1733.71
5 years
11.9833.71
10 years
11.9880.71
| Managers | Title | Age | Since |
|---|---|---|---|
Richard Pops
CEO | Chief Executive Officer | 62 | 91-01-31 |
Blair Jackson
DFI | Director of Finance/CFO | 51 | 98-12-31 |
Shane Cooke
PSD | President | 61 | 11-08-31 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Richard Pops
CEO | Chief Executive Officer | 62 | 91-01-31 |
Nancy Snyderman
BRD | Director/Board Member | 72 | 16-05-25 |
Brian McKeon
BRD | Director/Board Member | 61 | 20-12-09 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 15.32% | 215 M€ | +10.80% | - | |
| 2.65% | 1 M€ | -4.80% | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-05-03 | 24.05 | +0.80% | 1,347,148 |
| 24-05-02 | 23.86 | -0.62% | 1,987,877 |
| 24-05-01 | 24.01 | -2.16% | 2,843,963 |
| 24-04-30 | 24.54 | -1.37% | 2,168,589 |
| 24-04-29 | 24.88 | +0.81% | 1,709,228 |
Delayed Quote Nasdaq, May 03, 2024 at 04:30 pm EDT
More quotes
Alkermes plc is a global biopharmaceutical company that seeks to develop medicines in the field of neuroscience. The Company has a portfolio of commercial products for the treatment of alcohol dependence, opioid dependence, schizophrenia and bipolar I disorder and a pipeline of clinical and preclinical candidates in development for neurological disorders. It focuses on commercial products, such as LYBALVI, ARISTADA/ARISTADA INITIO and VIVITROL, and advancing the development of pipeline programs focused on neurological disorders. LYBALVI is a once-daily, oral atypical antipsychotic drug for the treatment of adults with schizophrenia and for the treatment of adults with bipolar I disorder, as a maintenance monotherapy or for the acute treatment of manic or mixed episodes, as monotherapy or an adjunct to lithium or valproate. ARISTADA is an extended-release intramuscular injectable suspension for the treatment of schizophrenia. It has a manufacturing facility in Wilmington, Ohio.
Calendar
2024-05-31
- Annual General Meeting
Related indices
Trading Rating
Investor Rating
ESG Refinitiv
B
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
12
Last Close Price
24.05
USD
Average target price
33.82
USD
Spread / Average Target
+40.62%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -13.30% | 4.07B | |
| +25.69% | 47.86B | |
| +46.90% | 41.42B | |
| -3.46% | 40.66B | |
| -6.20% | 28.92B | |
| +9.17% | 25.55B | |
| -20.42% | 19.27B | |
| +28.07% | 12.14B | |
| +0.17% | 12.15B | |
| -1.24% | 11.99B |
- Stock Market
- Equities
- ALKS Stock
